Stryker delivered robust financial results in Q2 2025, with consolidated net sales reaching $6.0 billion, an 11.1% increase, and adjusted diluted EPS growing by 11.4% to $3.13. The company saw strong organic net sales growth of 10.2%, with significant contributions from both MedSurg and Neurotechnology, and Orthopaedics.
Consolidated net sales increased 11.1% to $6.0 billion, with organic net sales up 10.2%.
Adjusted net earnings per diluted share grew 11.4% to $3.13.
MedSurg and Neurotechnology net sales increased 17.3% to $3.8 billion, while Orthopaedics net sales increased 2.0% to $2.2 billion.
Reported operating income margin was 18.5%, and adjusted operating income margin was 25.7%.
Stryker is raising its full-year 2025 guidance, expecting continued strong organic net sales growth and adjusted net earnings per diluted share.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance